Doxapram

Drug Profile

Doxapram

Alternative Names: Dopram

Latest Information Update: 07 Jun 2017

Price : $50

At a glance

  • Originator Unknown
  • Developer Kissei Pharmaceutical; Unknown
  • Class Morpholines; Pyrrolidinones; Respiratory stimulants; Small molecules
  • Mechanism of Action Central nervous system stimulants; Chemoreceptor cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Apnoea; Respiratory insufficiency

Most Recent Events

  • 20 Mar 2015 Registered for Apnoea (In neonates) in Japan (IV)
  • 20 May 2014 Preregistration for Apnoea (in neonates) in Japan (IV)
  • 01 Jan 1995 Launched for Respiratory insufficiency (in adults) in USA, Europe, China and India (IV) prior to 1995
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top